SG11201601203TA - Pidotimod for use in the treatment of inflammation-associated diseases - Google Patents
Pidotimod for use in the treatment of inflammation-associated diseasesInfo
- Publication number
- SG11201601203TA SG11201601203TA SG11201601203TA SG11201601203TA SG11201601203TA SG 11201601203T A SG11201601203T A SG 11201601203TA SG 11201601203T A SG11201601203T A SG 11201601203TA SG 11201601203T A SG11201601203T A SG 11201601203TA SG 11201601203T A SG11201601203T A SG 11201601203TA
- Authority
- SG
- Singapore
- Prior art keywords
- pidotimod
- inflammation
- treatment
- associated diseases
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/068701 WO2015036009A1 (en) | 2013-09-10 | 2013-09-10 | Pidotimod for use in the treatment of inflammation-associated diseases |
| PCT/EP2014/069103 WO2015036370A1 (en) | 2013-09-10 | 2014-09-08 | Pidotimod for use in the treatment of inflammation-associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601203TA true SG11201601203TA (en) | 2016-03-30 |
Family
ID=49118554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601203TA SG11201601203TA (en) | 2013-09-10 | 2014-09-08 | Pidotimod for use in the treatment of inflammation-associated diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160213651A1 (en) |
| EP (2) | EP3146966A1 (en) |
| JP (1) | JP2016529327A (en) |
| KR (1) | KR20160052582A (en) |
| CN (1) | CN105555267A (en) |
| AU (1) | AU2014320474A1 (en) |
| CA (1) | CA2922739A1 (en) |
| CL (1) | CL2016000543A1 (en) |
| EA (1) | EA201690574A1 (en) |
| HK (1) | HK1223041A1 (en) |
| IL (1) | IL244435A0 (en) |
| MD (1) | MD20160040A2 (en) |
| MX (1) | MX2016003195A (en) |
| PE (1) | PE20160649A1 (en) |
| PH (1) | PH12016500472A1 (en) |
| SG (1) | SG11201601203TA (en) |
| TW (1) | TW201542206A (en) |
| WO (2) | WO2015036009A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108003221B (en) * | 2017-12-14 | 2020-08-11 | 北京金城泰尔制药有限公司 | Process for removing pidotimod condensation impurities |
| KR102068289B1 (en) | 2018-06-20 | 2020-01-20 | 남희정 | Lens exchangeable glasser |
| CN113577242B (en) * | 2021-04-20 | 2023-12-08 | 中山大学附属第五医院 | Application of NLRP12 in preparing medicine for treating coronavirus infection or related inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230706B (en) * | 1989-02-10 | 1991-10-29 | Poli Ind Chimica Spa | DERIVATIVES OF ACID 3 PIROGLUTAMOIL THIAZOLIDIN 4 CARBOXYLIC AND THEIR PHARMACOLOGICAL PROPERTIES. |
| IT1231723B (en) | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | PYROGLUTAMIC ACID DERIVATIVES, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| IT1240353B (en) * | 1990-03-30 | 1993-12-07 | Poli Ind Chimica Spa | LIPOSOMAL FORMULATIONS OF IMMUNOMODULATING DRUGS FOR LOCAL AND AEROSOL APPLICATION |
| CN1225245C (en) * | 2004-01-16 | 2005-11-02 | 太阳石（唐山）药业有限公司 | Use of Pidotimod in preparation of hepatitis B treating medicine |
| EA201591185A1 (en) * | 2012-12-19 | 2016-02-29 | Полихем С.А. | APPLICATION OF PIDOTIMODE FOR THE TREATMENT OF PSORIASIS |
| PL2934520T3 (en) * | 2012-12-19 | 2017-08-31 | Polichem Sa | Use of pidotimod to treat atopic dermatitis |
| KR20150012167A (en) * | 2013-07-24 | 2015-02-03 | 주식회사 포벨 | Optical module for high speed communication |
-
2013
- 2013-09-10 WO PCT/EP2013/068701 patent/WO2015036009A1/en active Application Filing
-
2014
- 2014-09-03 TW TW103130366A patent/TW201542206A/en unknown
- 2014-09-08 WO PCT/EP2014/069103 patent/WO2015036370A1/en active Application Filing
- 2014-09-08 MX MX2016003195A patent/MX2016003195A/en unknown
- 2014-09-08 AU AU2014320474A patent/AU2014320474A1/en not_active Abandoned
- 2014-09-08 SG SG11201601203TA patent/SG11201601203TA/en unknown
- 2014-09-08 CN CN201480049183.4A patent/CN105555267A/en active Pending
- 2014-09-08 US US14/917,301 patent/US20160213651A1/en not_active Abandoned
- 2014-09-08 PE PE2016000351A patent/PE20160649A1/en not_active Application Discontinuation
- 2014-09-08 MD MDA20160040A patent/MD20160040A2/en not_active Application Discontinuation
- 2014-09-08 EA EA201690574A patent/EA201690574A1/en unknown
- 2014-09-08 JP JP2016541907A patent/JP2016529327A/en active Pending
- 2014-09-08 EP EP16197220.3A patent/EP3146966A1/en not_active Withdrawn
- 2014-09-08 CA CA2922739A patent/CA2922739A1/en not_active Abandoned
- 2014-09-08 KR KR1020167007206A patent/KR20160052582A/en not_active Application Discontinuation
- 2014-09-08 EP EP14761638.7A patent/EP3043796A1/en not_active Withdrawn
-
2016
- 2016-03-03 IL IL244435A patent/IL244435A0/en unknown
- 2016-03-09 CL CL2016000543A patent/CL2016000543A1/en unknown
- 2016-03-10 PH PH12016500472A patent/PH12016500472A1/en unknown
- 2016-09-29 HK HK16111420.9A patent/HK1223041A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2922739A1 (en) | 2015-03-19 |
| PH12016500472A1 (en) | 2016-05-16 |
| WO2015036370A1 (en) | 2015-03-19 |
| EP3146966A1 (en) | 2017-03-29 |
| EP3043796A1 (en) | 2016-07-20 |
| TW201542206A (en) | 2015-11-16 |
| KR20160052582A (en) | 2016-05-12 |
| HK1223041A1 (en) | 2017-07-21 |
| WO2015036009A1 (en) | 2015-03-19 |
| MX2016003195A (en) | 2016-11-14 |
| AU2014320474A1 (en) | 2016-03-24 |
| CL2016000543A1 (en) | 2016-11-04 |
| US20160213651A1 (en) | 2016-07-28 |
| PE20160649A1 (en) | 2016-07-09 |
| MD20160040A2 (en) | 2016-07-31 |
| EA201690574A1 (en) | 2016-09-30 |
| JP2016529327A (en) | 2016-09-23 |
| CN105555267A (en) | 2016-05-04 |
| IL244435A0 (en) | 2016-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274646A (en) | Integrated continuous manufacturing of therapeutic protein drug substances | |
| HK1216251A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| HK1222552A1 (en) | Sobetirome in the treatment of myelination diseases | |
| GB201517215D0 (en) | Use of cannabinoids in the treatment of inflammatory skin diseases | |
| HK1221178A1 (en) | Cabozantinib dosage form and use in the treatment of cancer | |
| HUE061618T2 (en) | Compound for use in the treatment of ocular disorders | |
| PL3004108T3 (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease | |
| PL3004112T3 (en) | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease | |
| PL3277280T3 (en) | Isomyosmine for use in the treatment of autoimmune diseases | |
| EP2943189A4 (en) | Methods and comp0stions for treatment of demyelinating diseases | |
| PL3466425T3 (en) | Use of glutarimide derivatives in the treatment of eosinophilic diseases | |
| EP2967062A4 (en) | Desethylhydroxychloroquine for the treatment of diseases associated with inflammation | |
| EP2949651A4 (en) | Substituted benzothiazoles and therapeutic uses thereof for the treatment of human diseases | |
| HK1221190A1 (en) | The local treatment of inflammatory ophthalmic diseases | |
| IL246855A0 (en) | Agents for use in the treatment of retinal inflammation | |
| EP2948140A4 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| HK1223041A1 (en) | Pidotimod for use in the treatment of inflammation-associated diseases | |
| EP2981324A4 (en) | Methods and articles of manufacture for the treatment of skin | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases | |
| EP2970152A4 (en) | Preparation and method for use in the treatment of respiratory diseases | |
| AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| TH1401006421A (en) | Compounds for use in the manufacture of drugs for the treatment of steroid-responsive skin diseases. | |
| HUP1300454A2 (en) | Pharmaceutical compositions for the treatment and prevention of tumorous diseases |